Smith and Williams' Introduction to the Principles of Drug Design and Action

Höfundar: H. John Smith; Hywel Williams (Útgáfa: 4)
Smith and Williams' Introduction to the Principles of Drug Design and Action

Kaup valmöguleikar

Nánar um bókina

Útgefandi
Taylor & Francis
ISBN
9781135299750
Print ISBN
9781032306612
Format
ePub
Útgáfa
4
Höfundar
H. John Smith; Hywel Williams
Tungumál
English
Útgefið
2005-10-10
Prent takmörkun á líftíma
100
Prent takmörkun
2
Afritunar takmörkun
2

Kaflar

  • Cover Page
  • Title Page
  • Copyright Page
  • Preface
  • List of Contributors
  • Abbreviations
  • 1. Processes of Drug Handling by the Body
  • 1.1 Introduction
  • 1.2 Absorption
  • 1.3 Distribution
  • 1.4 Metabolism
  • 1.5 Removal of Drugs from the Body
  • 1.6 Summary
  • Further Reading
  • 2. The Design of Drug Delivery Systems
  • 2.1 Introduction
  • 2.2 Formulation Aims
  • 2.3 Physico-Chemical Factors Influencing Drug Bioavailability
  • 2.4 Influence of Route of Administration and Type of Dosage Form
  • 2.5 Formulation Factors
  • 2.6 Drug Delivery to the Lung
  • 2.7 Sustained and Controlled Release Dosage Forms
  • 2.8 Site-Specific Drug Delivery
  • 2.9 Bioequivalence
  • Further Reading
  • 3. Intermolecular Forces and Molecular Modelling
  • 3.1 Introduction
  • 3.2 Molecular Interactions
  • 3.3 Free Energies of Interaction—Gas phase and Solution
  • 3.4 Intramolecular Forces and Conformation
  • 3.5 Molecular Modelling
  • 3.6 Proteins
  • 3.7 Accurate Calculation of Intermolecular Interactions
  • References
  • 4. Drug Chirality and Its Pharmacological Consequences
  • 4.1 Introduction
  • 4.2 Definitions and Nomenclature
  • 4.3 Biological Activity
  • 4.4 Pharmacokinetic Considerations
  • 4.5 Pharmacodynamic Considerations
  • 4.6 Selected Therapeutic Groups
  • 4.7 Toxicology
  • 4.8 Racemates Versus Enantiomers: The Future
  • 4.9 Concluding Comment
  • Further Reading
  • 5. Quantitative Structure-Activity Relationships and Drug Design
  • 5.1 Introduction
  • 5.2 Hydrophobicity Parameters
  • 5.3 Electronic Parameters
  • 5.4 Steric Parameters
  • 5.5 Topological Parameters
  • 5.6 Biological Relationships
  • 5.7 Some Limitations and Pitfalls of QSAR
  • 5.8 Multivariate Analysis
  • 5.9 Neural Networks
  • 5.10 Summary
  • Further Reading
  • 6. From Programme Sanction to Clinical Trials: A Partial View of the Quest for Arimidex™, A Potent, Selective Inhibitor of Aromatase
  • 6.1 Introduction
  • 6.2 Background
  • 6.3 ICI Start on Aromatase Inhibition
  • 6.4 Aromatase Resumed
  • 6.5 Bis-Triazole (6.17)—A Timely Aromatase Compound in Development
  • 6.6 The Search for the Ideal Back-Up Candidate
  • 6.7 Into the Clinic
  • Further Reading
  • 7. Pro-Drugs
  • 7.1 Introduction
  • 7.2 Pro-Drug Design
  • 7.3 Application to Pharmaceutical Problems
  • 7.4 Pharmacological Problems
  • 7.5 Summary
  • Further Reading
  • 8. Design of Enzyme Inhibitors as Drugs
  • 8.1 Introduction
  • 8.2 General Aspects of Inhibitor Design
  • 8.3 Rational Approach to the Design of Enzyme Inhibitors
  • 8.4 Development of a Successful Drug for the Clinic
  • 8.5 Stereoselectivity
  • 8.6 Examples of Enzyme Inhibitors as Drugs
  • Further Reading
  • 9. The Chemotherapy of Cancer
  • 9.1 Introduction
  • 9.2 Terminology
  • 9.3 Metastases
  • 9.4 Cell Growth Cycle
  • 9.5 Mechanisms of Tumour Formation
  • 9.6 Treatment
  • 9.7 Antimetabolites
  • 9.8 DNA Interactive Compounds
  • 9.9 Antitubulin Agents
  • 9.10 Miscellaneous Agents
  • 9.11 Immunosuppressive Agents
  • 9.12 Anti-Hormonal Agents
  • 9.13 Enzymes
  • 9.14 Biologicals
  • 9.15 Prodrugs and Drug Targeting Approaches
  • 9.16 New Research Tools
  • 9.17 Future Possibilities
  • 9.18 Anti-Emetics
  • Further Reading
  • 10. Neurotransmitters, Agonists and Antagonists
  • 10.1 Overview
  • Further Reading
  • 10.2 Serotonin Receptors and Ligands
  • Further Reading
  • 10.3 Histamine Receptors
  • Further Reading
  • 10.4 Dopamine Receptors
  • Further Reading
  • 11. Design of Antimicrobial Chemotherapeutic Agents
  • 11.1 Introduction
  • 11.2 Production of Chemotherapeutic Agents
  • 11.3 Mechanism of Action of Chemotherapeutic Agents
  • 11.4 Bacterial Resistance to Chemotherapeutic Agents
  • 11.5 Design of β-Lactam Antibiotics
  • 11.6 Design of Other Antibacterial Agents
  • 11.7 Design of Antifungal Agents
  • 11.8 Design of Antiviral Agents
  • 11.9 Overall Conclusions and Comments
  • Further Reading
  • 12. Recombinant DNA Technology: Monoclonal Antibodies
  • 12.1 Recombinant DNA Technology
  • 12.2 Monoclonal Antibodies
  • Further Reading
  • 13. Bio-Inorganic Chemistry and Its PharmaceuticaL Applications
  • 13.1 Introduction
  • 13.2 The Importance of Trace Elements in Humans
  • 13.3 Metal Coordination Chemistry
  • 13.4 PHarmacological and Pharmaceutical Considerations
  • 13.5 Metals as the Modus Operandi of Drugs
  • 13.6 Drugs which Exert Their Effects Via Metal Complexation or Chelation
  • 13.7 Metal-Dependent Side Effects of Drugs
  • 13.8 Trace Element Supplementation
  • 13.9 Concluding Remarks
  • Further Reading